I was living a normal 29-year-old life. I thought my symptoms were no big deal, until they started happening more ...

Pancreatic cancer is notoriously hard to treat, often resisting therapies that target its most common mutations. Researchers ...

An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...

The number and frequency of intravesical instillations for non-muscle-invasive bladder cancer (NMIBC) impairs quality of life and needs to be reported in clinical trials.

A research team at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has developed a radiopharmaceutical molecule marker that ...

New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...

New research from University of Lucknow and King George’s Medical University shows that specific protein markers involved in ...

Bladder cancer treatment depends on whether it is superficial or muscle invasive. Muscle-invasive bladder cancer or MIBC does ...

The "Pipeline of TROP-2-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering. This competitive intelligence report about TROP-2-Targeted Immunotherapies provides a ...

Confronting the Diagnosis Upon diagnosis of the aggressive bladder cancer, the 58-year-old Sanders underwent prompt surgery to have his bladder removed and later reconstructed with a portion of his ...

In an exclusive interview, Colorado coach Deion Sanders opens up about the cancer fight that transformed his life, managing the demands of coaching with sustainable health habits, and the one ...